LDX shareholder equity before any products and FDA approval sits around 7.5c (~$31m AUD in shareholder equity)
Approval of FebriDx under a 510(k) FDA submission normally costs around an average $31m USD (~$48m AUD) depending on complexity, putting shareholder equity value at around $79m AUD or 19c.
That is before any agreements or sales into a roughly $170 billion USD, US medical devices market. So undervalued!!!
I think someone should start a $1 party thread!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $19.46M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.6¢ | 2.6¢ | $3.617K | 139.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 251316 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 697354 | 2 |
View Market Depth
| Last trade - 15.59pm 27/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |